• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Taxanes and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Diterpenoids Taxanes and derivatives

Comprehensive Overview of Docetaxel Metabolite M4 (CAS No. 157067-34-0): Properties, Applications, and Research Insights

Docetaxel Metabolite M4 (CAS No. 157067-34-0) is a critical intermediate in the metabolism of Docetaxel, a widely used chemotherapeutic agent. This metabolite has garnered significant attention in pharmaceutical research due to its role in understanding drug efficacy and patient response. Researchers and clinicians are increasingly focusing on Docetaxel Metabolite M4 to optimize cancer treatment protocols and minimize adverse effects.

The chemical structure of Docetaxel Metabolite M4 features a taxane core, similar to its parent compound, but with distinct modifications that influence its pharmacokinetics. These structural nuances make it a valuable subject for studies on drug metabolism and personalized medicine. Recent advancements in analytical techniques, such as LC-MS/MS, have enabled precise quantification of Docetaxel Metabolite M4 in biological samples, paving the way for more accurate therapeutic monitoring.

One of the most frequently searched questions about Docetaxel Metabolite M4 is its role in drug resistance and cancer recurrence. Studies suggest that variations in metabolite levels may correlate with treatment outcomes, making it a potential biomarker for predicting patient response. This aligns with the growing trend in precision oncology, where metabolites like M4 are used to tailor therapies for individual patients.

In addition to its clinical relevance, Docetaxel Metabolite M4 is also a focus of pharmacokinetic modeling. Researchers utilize this metabolite to develop computational models that simulate drug behavior in the human body. Such models are instrumental in reducing the time and cost associated with drug development, a topic of high interest in the pharmaceutical industry.

The market for Docetaxel Metabolite M4 is expanding, driven by the rising demand for reference standards in bioanalytical labs. Companies specializing in high-purity chemicals are investing in the synthesis and characterization of this metabolite to support ongoing research. This trend reflects the broader shift toward quality control and regulatory compliance in drug development.

Another hot topic linked to Docetaxel Metabolite M4 is its potential role in combination therapies. Preclinical studies are exploring how this metabolite interacts with other anticancer agents to enhance therapeutic efficacy. These investigations are particularly relevant in the context of refractory cancers, where traditional treatments often fail.

From a technical standpoint, the synthesis of Docetaxel Metabolite M4 requires specialized expertise in organic chemistry and chromatography. The process involves multiple steps to ensure high yield and purity, making it a challenging yet rewarding endeavor for synthetic chemists. This complexity underscores the importance of collaborative research between academia and industry.

In summary, Docetaxel Metabolite M4 (CAS No. 157067-34-0) is a compound of immense scientific and clinical significance. Its applications span from biomarker discovery to drug development, making it a cornerstone of modern oncology research. As the field of personalized medicine evolves, the study of metabolites like M4 will continue to shape the future of cancer treatment.

• 183133-96-2(Cabazitaxel)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)